# A Combination of Amaranth Protein Hydrolysate and Korean Mint Extract Ameliorates Cisplatin-Induced Nephrotoxicity and Cachexia in CT26 Tumor-Bearing BALB/c Mice

**Authors:** Junhee Lee, Yeeun Kim, Mi-Bo Kim, Ju Hyun Park, Daedong Kim, Dong-Woo Lee, Jae-Kwan Hwang

PMC · DOI: 10.3390/nu18040665 · Nutrients · 2026-02-18

## TL;DR

A combination of amaranth protein hydrolysate and Korean mint extract reduces kidney damage and muscle loss in mice undergoing chemotherapy for cancer.

## Contribution

A novel combination therapy using amaranth protein hydrolysate and Korean mint extract is shown to alleviate cisplatin-induced nephrotoxicity and cachexia in tumor-bearing mice.

## Key findings

- AKE reduced body weight loss and systemic inflammation in cisplatin-treated tumor-bearing mice.
- AKE preserved skeletal muscle and adipose tissue mass and improved renal function markers.
- AKE modulated protein turnover pathways and suppressed renal apoptosis in mice.

## Abstract

Background/Objectives: Cancer cachexia involves progressive skeletal muscle and adipose tissue loss, which is further aggravated by cisplatin chemotherapy via increased systemic inflammation, tissue catabolism, and renal toxicity. The present study aimed to evaluate whether a combination of amaranth protein hydrolysate and Agastache rugosa extract (AKE) could attenuate cisplatin-associated cachexia and nephrotoxicity in CT26 tumor-bearing mice. Methods: Cancer cachexia was induced by subcutaneous CT26 cell inoculation in 6-week-old male BALB/c mice, followed by a 7-day tumor establishment period. Cisplatin was then administered intraperitoneally, and AKE (125 or 250 mg/kg/day) was given daily by oral gavage for 14 days. Results: AKE administration significantly alleviated cisplatin-induced body weight loss and systemic inflammation, accompanied by preservation of skeletal muscle and adipose tissue mass, as well as increased myofiber cross-sectional area and adipocyte size. AKE markedly reduced serum inflammatory cytokines, blood urea nitrogen, and creatinine levels, indicating protection against cisplatin-induced renal injury. Mechanistically, AKE suppressed renal apoptosis through inhibition of mitogen-activated protein kinase signaling. In skeletal muscle, AKE attenuated muscle atrophy by modulating protein turnover pathways, including downregulation of muscle-specific ubiquitin ligases and restoration of Akt/mTOR and FoxO3a signaling. Furthermore, AKE mitigated adipose tissue wasting by suppressing AMP-activated protein kinase-dependent browning and restoring adipogenic signaling involved in lipid storage and differentiation. Conclusions: These findings demonstrate that AKE confers comprehensive protection against cisplatin-induced cachexia and nephrotoxicity by coordinately preserving muscle and adipose tissue and attenuating renal injury, suggesting its potential as a functional nutritional strategy to alleviate chemotherapy-associated tissue wasting.

## Linked entities

- **Proteins:** AKT1 (AKT serine/threonine kinase 1), MTOR (mechanistic target of rapamycin kinase), FOXO3 (forkhead box O3)
- **Chemicals:** cisplatin (PubChem CID 5460033), creatinine (PubChem CID 588)

## Full-text entities

- **Genes:** Foxo3 (forkhead box O3) [NCBI Gene 56484] {aka 1110048B16Rik, 2010203A17Rik, FKHRL1, Fkhr2, Foxo3a}, Pik3r1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 18708] {aka PI3K, p50alpha, p55alpha, p85alpha}, Cebpa (CCAAT/enhancer binding protein alpha) [NCBI Gene 12606] {aka C/ebpalpha, CBF-A, Cebp}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, Ppargc1a (peroxisome proliferative activated receptor, gamma, coactivator 1 alpha) [NCBI Gene 19017] {aka A830037N07Rik, Gm11133, PGC-1, PPARGC-1-alpha, Pgc-1alpha, Pgc1}, Cish (cytokine inducible SH2-containing protein) [NCBI Gene 12700] {aka CIS-1, CIS1, Cis, F17, F23, SOCS}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, Srebf1 (sterol regulatory element binding transcription factor 1) [NCBI Gene 20787] {aka ADD1, SREBP1, bHLHd1}, Mapk1 (mitogen-activated protein kinase 1) [NCBI Gene 26413] {aka 9030612K14Rik, ERK, Erk2, MAPK2, PRKM2, Prkm1}, Bcl2 (B cell leukemia/lymphoma 2) [NCBI Gene 12043] {aka Bcl-2, C430015F12Rik, D630044D05Rik, D830018M01Rik}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56717] {aka 2610315D21Rik, FRAP, FRAP2, Frap1, RAFT1, RAPT1}, Mapk14 (mitogen-activated protein kinase 14) [NCBI Gene 26416] {aka CSBP2, Crk1, Csbp1, Mxi2, PRKM14, PRKM15}, Ucp1 (uncoupling protein 1 (mitochondrial, proton carrier)) [NCBI Gene 22227] {aka Slc25a7, Ucp}, Mapk8 (mitogen-activated protein kinase 8) [NCBI Gene 26419] {aka JNK, JNK1, Prkm8, SAPK1}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Bax (BCL2-associated X protein) [NCBI Gene 12028], Pparg (peroxisome proliferator activated receptor gamma) [NCBI Gene 19016] {aka Nr1c3, PPAR-gamma, PPAR-gamma2, PPARgamma, PPARgamma2}, Fbxo32 (F-box protein 32) [NCBI Gene 67731] {aka 4833442G10Rik, ATROGIN1, Gm20361, MAFbx}, Trim63 (tripartite motif-containing 63) [NCBI Gene 433766] {aka MuRF1, RF1, Rnf28}, Casp3 (caspase 3) [NCBI Gene 12367] {aka A830040C14Rik, AC-3, CASP-3, CC3, CPP-32, CPP32}
- **Diseases:** metabolic dysregulation (MESH:D021081), dislocation (MESH:D004204), renal ischemia (MESH:D007511), renal (MESH:D006030), metabolic dysfunction (MESH:D008659), colon carcinoma (MESH:D003110), tissue injury (MESH:D017695), organ damage (MESH:D000092124), multi-organ dysfunction (MESH:D009102), Renal Injury (MESH:D007674), adipose (MESH:D018205), AKI (MESH:D058186), wasting (MESH:D019282), Cachexia (MESH:D002100), muscle loss (MESH:D009135), Cancer (MESH:D009369), metabolic insufficiency (MESH:D000309), organ toxicity (MESH:D019965), CKI (MESH:D051436), Weight Loss (MESH:D015431), cytotoxicity (MESH:D064420), renal cortical tubular injury (MESH:D015499), reperfusion injury (MESH:D015427), injury (MESH:D014947), Inflammation (MESH:D007249), Muscle Atrophy (MESH:D009133), lung, bladder, ovarian, head and neck, and colorectal cancers (MESH:D013577), mitochondrial dysfunction (MESH:D028361), pain (MESH:D010146), nutritional deficiency (MESH:D044342), deaths (MESH:D003643)
- **Chemicals:** SDS (MESH:D012967), eosin (MESH:D004801), lysine (MESH:D008239), essential amino acid (MESH:D000601), formalin (MESH:D005557), creatinine (MESH:D003404), flavonoid (MESH:D005419), CO2 (MESH:D002245), E (MESH:D004540), amaranth (MESH:D000548), water (MESH:D014867), LPS (MESH:D008070), urea nitrogen (MESH:C530477), lipid (MESH:D008055), tilianin (MESH:C426884), Avertin (MESH:C062527), amino acid (MESH:D000596), streptomycin (MESH:D013307), daidzein (MESH:C004742), S (MESH:D013455), H&amp;E (MESH:D006371), platinum (MESH:D010984), Cisplatin (MESH:D002945), Agastache rugosa extract (-), paraffin (MESH:D010232), penicillin (MESH:D010406), hematoxylin (MESH:D006416), linalool (MESH:C018584)
- **Species:** Agastache rugosa (species) [taxon 39271], Amaranthus caudatus (amaranth, species) [taxon 3567], Mus musculus (house mouse, species) [taxon 10090], Almidae sp. Ke (species) [taxon 1046270], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** 7A-C
- **Cell lines:** CT26 — Mus musculus (Mouse), Mouse colon adenocarcinoma, Cancer cell line (CVCL_7254), BALB/c — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0184)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12942734/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12942734/full.md

## References

43 references — full list in the complete paper: https://tomesphere.com/paper/PMC12942734/full.md

---
Source: https://tomesphere.com/paper/PMC12942734